Ultra Health, a medical cannabis company in New Mexico, has partnered with Israeli pharmaceutical group Panaxia to manufacture pharmaceutical-grade medical cannabis products like oils, sublingual tablets, patches, topical creams and suppositories.

A 5,000-square foot production facility was constructed on Ultra Health’s property in Bernalillo, New Mexico and houses Panaxia’s state-of-the-art technology not previously available in the United States.

These improvements included a validated analytical system and proprietary production technology, which Dr. Dadi Segal, CEO of Panaxia, said will make products more useful to patients and doctors.

“Our idea is to offer products to those patients who will not try the benefits of cannabis because they can’t use it like any other medication,” Segal added.

Ultra Health currently manufactures 28 Panaxia products containing specific doses of tetrahydrocannabinol (THC) and cannabidiol (CBD) to suit the patient’s medical needs. THC is a compound of the cannabis plant which gives consumers a psychological “high,” while the CBD compound contains medical properties but gives no high to the consumer.

At Ultra Health, our mission is to provide superior-quality and affordable medical grade cannabis to New Mexico patients,” Duke Rodriguez, CEO and President of Ultra Health, said in a press release. “Ultra Health is driven by compassionate innovation and supported by science and technology. It is important that we develop new products in anticipation of meeting the rapidly growing patient and provider demands.”